THE IDENTIFICATION OF THE 3' TERMINUS OF THE 70 S RNA OF MURINE SARCOMA VIRUS (MOLONEY)

Jacqueline ROBIN, Christian Jacques LARSEN, Rodica Emanoïl RAVICOVITCH, Monique BAZILIER, Martine MAUCHAUFFE and Michel BOIRON

Institut de Recherches sur les Maladies du Sang, Laboratoire d'Hématologie Expérimentale Hôpital Saint-Louis, 75010 Paris, France

Received 7 August 1972

1. Introduction

The major nucleic acid component of Oncornaviruses is a high molecular weight RNA that sediments between 60 and 70 S. Its molecular weight has been estimated to be about 10^7 daltons [1]. It can be dissociated by heat or dimethyl sulfoxide into subunits that sediment at about 35 S [2].

Little is known about the primary structure of this 60–70 S RNA. The identification of the 3' terminus is a first approach in this analysis and may provide interesting information because the 3' terminus is apparently important for binding the RNA dependent-DNA polymerase of these viruses [3]. Uridine has been found to be the terminal base for 70 S RNA of several C-type viruses of avian, reptilian or mammalian origin [4, 5]. By using the method used by Rajbhandary [6] of labeling the 3' terminal nucleoside residues by periodate oxidation and subsequent reduction with sodium [3H] borohydride, we have identified uridine as the major terminal nucleoside of the 60–70 S RNA of the murine leukemia—sarcoma virus complex.

2. Materials and methods

2. 1. Preparation of viral RNA

Virus was obtained from the supernatant fluids of a chronically-infected cell line (78 A_1 cells) [7]. Viral RNA was isolated as previously described [8]. Polyvinylsulfate (10 μ g/ml) was systematically added during the course of isolation. 70 S RNA was separated

from the other molecular species in a 5-20% sucrose gradient.

 32 P-labeled virus was prepared by labeling cells for 24 hr with 20 μ Ci/ml of [32 P] ortho-phosphate carrier-free from CEA (Saclay).

2. 2. ³H-labeling of 3' terminal groups

The reaction conditions were essentially those described by Watcher and Fiers [9]. They were modified for small amounts of RNA. All manipulations were carried out at room temperature. RNA was dissolved in $50\,\mu$ l of $0.02\,M$ Na-acetate pH $5.1.5\,\mu$ l of $0.01\,M$ Na 10_4 were added. The solution was left in the dark for 1 hr. The oxidation step was stopped by $5\,\mu$ l of $0.1\,M$ ethyleneglycol. 30 min later, 1 ml of $0.5\,M$ phosphate buffer, pH 7, was added, then, 7 to 10 mCi of [3H]NaBH $_4$ (Radiochemical Centre, Amersham) dissolved in $0.1\,$ ml of $1\,M$ NaOH and stored at -20° (specific activity: $3\,$ Ci/mmole). The mixture was incubated in the dark for $1.5\,$ hr. $20\,\mu$ l of cyclohexanone were added to stop the reaction.

2. 3. Sephadex gel filtration

The reaction mixture was filtered through a Sephadex G-25 column (27 \times 2 cm) equilibrated with 0.02 M Na acetate pH 5.1 to eliminate excess borohydride. The tritiated RNA was precipitated with cold ethanol in the presence of 200 μ g of carrier cellular RNA.

4. Alkaline hydrolysis and determination of ³H-labeled terminal nucleoside derivatives
 [3H] RNA was hydrolyzed by 15 μl of 0.5 M NaOH for 18 hr at 37°. The hydrolysate was applied to a




Fig. 1. Sucrose gradient sedimentation of MSV-MLV complex RNA. A trace amount of viral [32 P] RNA was mixed with unlabeled viral RNA. Sedimentation was performed in a 5%-20% sucrose gradient in a Spinco SW 25 rotor at 25,000 rpm for 3.5 hr at 4°. The fractions corresponding to 70 S RNA were pooled and precipitated with ethanol.

Whatmann N°1 MM paper with a mixture of trialcohol nucleoside markers and subjected to high voltage electrophoresis in a solvent consisting of pyridine, acetic acid and water [5:5:90], pH 3.5, at 3,000 V for 1.5 hr.

The four nucleoside trialcohols were visualized in UV light. The paper was cut into 2 cm \times 1 cm pieces and 3 H radioactivity was counted with 10 ml of scintillantion solution.

2. 5. Preparation of trialcohol nucleoside derivatives
Nucleoside trialcohols were prepared according to
the method described by Wachter and Fiers [9].

3. Results

A trace amount of [³²P]virus was systematically mixed with unlabeled virus preparation in order to magnify the peaks of 70 S RNA during the purification procedures. Fig. 1 shows the profile of 70 S RNA purified in sucrose gradients.

The purified 70 S RNA was oxidized with metaperiodate and than reduced by sodium [³H] borohydride. The product isolated from the reaction mixture was filtered through Sephadex G-25 to separate the 70 S [³H]RNA and remove the bulk of non-bound ³H, as shown in fig. 2.

To identify the ³H-labeled 3'OH terminus, RNA was hydrolyzed by NaOH. Fig. 3 shows the typical ³H distribution in the alkaline hydrolysate on the electrophoretic paper. Radioactivity remaining at the origin has been reported [10, 11] but its nature has not been elucidated.

Table 1 shows the analysis of the distribution of ³H radioactivity in nucleoside trialcohols. For control purposes, we have included a comparative analy-

Table 1
3' Terminal nucleosides of viral 70 S RNA and various cell RNA's,

RNA source	% of ³ H radioactivity in nucleoside trialcohols			
	Adenosine		Guanosine	
MSV-MLV				
complex	11	3	9	77
70 S RNA				
78 A ₁ cells				
4 S RNA*	79	14	0	7
5 S RNA*	23	9	0	68
7 S RNA*	13	5	5	77
Total ribo-				
somal RNA*	41	2	2	55

The values in the table are average values.

^{*} The various cell RNA's were prepared according to methods described by Galibert et al. [17]. They were purified by sucrose gradients, chromatography on MAK columns and polyacrylamide gel electrophoresis.




Fig. 2. Sephadex G-25 filtration of ³H-labeled 70 S RNA. Reaction mixture was layered on a 2 cm \times 27 cm column of Sephadex G-25 equilibrated in 0.02 M Na acetate pH 5.1 and eluted with this buffer. $(\bullet - \bullet - \bullet)$ ³H radioactivity. $(\circ - \circ - \circ)$ ³²P radioactivity.

sis of the 3' termini of different RNA of 78 A₁ cells. The results for cellular RNA agree with results obtained for other cell RNA.

The determination of 3'OH terminal nucleoside of 70 S RNA was applied to three viral preparations. On each occasion about 80% of the radioactivity was found on uridine.

4. Discussion

In the present study, we have applied the technique

of periodate oxidation and [3H] borohydride reduction to identify the 3' terminal nucleoside of 60–70 S RNA of MSV–MLV complex. Since the borohydride reagent interacts with many compounds [12, 13], 70 S RNA was purified in sucrose gradients from smaller RNA's and from non RNA contaminants. However traces of 8 S and 4 S RNA associated with 70 S RNA and only released after heating (unpublished results) were not removed for this study.

Control experiments made with 78 A₁ RNA's are in agreement with data reported for other cell RNA's [14-16]. tRNA ends predominantly in A but




Fig. 3. Distribution of ³H radioactivity on electrophoretic paper of alkaline hydrolysate of RNA. (——) Radioactivity of ³H-end labeled viral 70 S RNA; (---) radioactivity of ³H-end labeled cell tRNA.

a few C residues are present because C is the penultimat 3' base. Some contamination by 5 S RNA can explain the presence of U since this molecular species ends in U. Some A and C are found for 5 S RNA because of 4 S RNA contamination. U is the major terminus of 7 S RNA which is linked to 28 S rRNA. The 3' termini of 28 S and 18 S rRNA's are U and A in the nearly same proportions as described for L cells rRNA's [14]. Therefore, our method seems most efficient for identifying the 3' terminus of RNA. Its application to 70 S RNA of MSV-MLV complex gave uridine as the major 3' end. As we were going on this investigation, U was found to be the predominant base in RNA of several tumor viruses (for 70 S RNA and 35 S subunits) [4, 5]. Our results are in accord with them. However, a different finding was recently

published by Stephenson et al. [10] who reported finding A as the terminal nucleoside of 70 S and 35 S RNA of avian myeloblastosis virus. To date, from this result which was not confirmed by Erikson, it cannot be concluded that all 70 S RNA molecules of Oncornaviruses end in U. Further studies should solve this open question.

Acknowledgements

The research upon which this publication is based was performed pursuant to Contract N° NIH-NCI-E72 3263 with the National Cancer Institute, National Institutes of Health, Department of Health, Education and Welfare. This research was also supported in part by a grant from the Council for Tobacco Research.

References

- [1] P.H. Duesberg, Current topics in Microbiology and Immunology 51 (1970) 79.
- [2] J.P. Bader and T.L. Steck, J. Virol. 4 (1969) 454.
- [3] J.P. Leis and J. Hurwitz, J. Virol. 9 (1972) 130.
- [4] H.B. Maruyama, M. Hatanaka and R.V. Gilden, Proc. Natl. Acad. Sci. U.S. 68 (1971) 1999.
- [5] R.L. Erikson, E. Erikson and T.A. Walker, Virology 45 (1971) 527.
- [6] U.L. Rajbhandary, J Biol. Chem. 243 (1968) 556.
- [7] C. Bernard, M. Boiron and J. Lasneret, Compt. Rend. 264 (1968) 2170.
- [8] R. Emanoïl Ravicovitch, C. Bernard and C.J. Larsen, Compt. Rend. 266 (1968) 1802.

- [9] R. De Wachter and W. Fiers, J. Mol. Biol. 30 (1967) 507.
- [10] M.L. Stephenson, Lr.L. Wirthlin, J.F. Scott and P.C. Zamecnik, Proc. Natl. Acad. Sci. U.S. 69 (1972) 1176.
- [11] Y. Furuichi and K. Miura, J. Mol. Biol. 64 (1967) 507.
- [12] L. J. Lewandowski, J. Content and S.H. Leppla, J. Vir. 8 (1971) 701.
- [13] S.H. Leppla, B. Bjoraker and R.M. Bock, Methods in Enzymology, 12 (1968) 236.
- [14] B.G. Lane and T. Tamaoki, J. Mol. Biol. 27 (1967) 335.
- [15] J.A. Hunt, Biochem. J. 120 (1970) 353.
- [16] B.G. Forget and S.M. Weissman, Science 158 (1967) 1695.
- [17] F. Galibert, C.J. Larsen, J.C. Lelong and M. Boiron, Bull. Soc. Chim. Biol. 48 (1966) 21.